Press Releases

 

Statement on Our Commitment to Diversity and Equality

Statement on COVID-19

As we continue to monitor COVID-19 developments, at Neurocrine Biosciences we are committed to the safety, health and well-being of our patients, customers and employees. To healthcare providers and their patients with tardive dyskinesia or Parkinson’s disease, we do not anticipate any disruption in our ability to supply INGREZZA® (valbenazine) or ONGENTYS® (opicapone). Be assured, we remain focused on our mission to discover, develop and deliver important medicines to treat patients with neurological, endocrine, and psychiatric disorders.


DateTitle 
6/1/21
SAN DIEGO , June 1, 2021 /PRNewswire/ --  Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Goldman Sachs 42 nd Annual Global Healthcare Conference at 1:20 p.m. Eastern Time on Tuesday, June 8, 2021 . Kevin Gorman , Chief Executive Officer, will present at the conference.
5/11/21
SAN DIEGO , May 11, 2021 /PRNewswire/ --  Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the 2021 RBC Capital Markets Healthcare Conference at 10:55 a.m. Eastern Time on Tuesday May 18, 2021 . Matt Abernethy , Chief Financial Officer, and Eiry Roberts, Chief Medical Officer, will
5/5/21
INGREZZA® (valbenazine) First Quarter 2021 Net Product Sales of $230 Million with Approximately 43,300 TRx Initiated Pediatric Phase III Registrational Program of Crinecerfont for the Treatment of Classic Congenital Adrenal Hyperplasia Initiated Phase II Study of NBI-827104 in Essential Tremor SAN
5/4/21
SAN DIEGO , May 4, 2021 /PRNewswire/ --  Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Bank of America 2021 Healthcare Conference at 11:00 a.m. Eastern Time on Tuesday May 11, 2021 . Kevin Gorman , Chief Executive Officer, will present at the conference.
5/3/21
- Mental Health Advocacy Community Recognizes and Over 40 States Declare First Week of May (2-8) Tardive Dyskinesia Awareness Week to Raise Awareness of this Burdensome and Often Misunderstood Condition - Recent Survey Results Show That More Than Half (60%) of People Living With Diagnosed or
4/16/21
SAN DIEGO , April 16, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of Johanna Mercier to its Board of Directors. Ms. Mercier is the Chief Commercial Officer of Gilead Sciences, with responsibility for the global commercialization of Gilead's
4/14/21
Conference Call and Webcast Scheduled for Wednesday, May 5 SAN DIEGO , April 14, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will report first quarter 2021 financial results after the Nasdaq market closes on Wednesday, May 5, 2021 .
4/8/21
SAN DIEGO , April 8, 2021 /PRNewswire/ -- Neurocrine Biosciences , Inc. (Nasdaq: NBIX) today announced that it will present data from its movement disorders and epilepsy programs at the American Academy of Neurology's (AAN) 73rd Annual Meeting being held virtually from April 17–22, 2021.
3/25/21
SAN DIEGO , March 25, 2021 /PRNewswire/ --  Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Stifel 3 rd Annual CNS Day at 12:30 p.m. Eastern Time on Thursday Apr. 1, 2021 . Eiry Roberts, Chief Medical Officer, and Kyle Gano , Chief Business Development and Strategy Officer, will
3/20/21
- Additional Positive Data from Phase II CAHlibrate Study - Real-World Data Highlight Impact of CAH in Adult and Pediatric Patients SAN DIEGO , March 20, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present additional positive data from its Phase II
3/9/21
SAN DIEGO , March 9, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Oppenheimer 31 st Annual Healthcare Conference at 4:30 p.m. Eastern Time on Tuesday Mar. 16, 2021 . Matt Abernethy , Chief Financial Officer, will present at the conference.
3/2/21
- Negative Outcome on Primary Endpoint Measured by the Change from Baseline on the Positive and Negative Syndrome Scale/Negative Symptom Factor Score (PANSS NSFS) - Positive Outcome on Cognitive Assessment Secondary Endpoints Support Potential Further Clinical Development of Luvadaxistat - No New
2/23/21
SAN DIEGO , Feb. 23, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Cowen 41 st Annual Health Care Conference at 1:30 p.m. Eastern Time on Tuesday Mar. 2, 2021 . Kevin Gorman , Chief Executive Officer, will present at the conference.
2/4/21
Total Annual Revenues in 2020 Grew 33% to Over $1 Billion INGREZZA® (valbenazine) Full Year 2020 Net Product Sales and TRx Both Grew 32% to $993 Million and Approximately 175,700 TRx, Respectively Mitsubishi Tanabe Pharma Corporation (MTPC) Reports Successful Top-Line Results for Asia-Based
1/20/21
Conference Call and Webcast Scheduled for Thursday, February 4 SAN DIEGO , Jan. 20, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will report fourth quarter and year-end 2020 financial results after the Nasdaq market closes on Thursday, Feb. 4, 2021 .
1/8/21
INGREZZA® (valbenazine) Preliminary Fourth Quarter Net Product Sales and Inventory Adjusted Net Product Sales of Approximately $240 Million and $258 Million, Respectively INGREZZA® (valbenazine) Preliminary Full-Year 2020 Net Product Sales and TRx Both Grew 32% to Approximately $993 Million and
1/4/21
SAN DIEGO , Jan. 4, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the 39 th Annual J.P. Morgan Healthcare Conference at 2:00 p.m. Eastern Time on Monday Jan. 11, 2021 . Kevin Gorman , Chief Executive Officer, will present at the conference.